Abiomed (ABMD) Receives FDA Pre-Market Approval for Impella Therapy for Cardiogenic Shock
Tweet Send to a Friend
Abiomed, Inc. (NASDAQ: ABMD) announced that it has received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
